17.4 Class III: Potassium Channel Blockers

Class III Antiarrhythmic Drugs: Potassium Channel Blockers

Class III antiarrhythmics work by blocking potassium channels in cardiac cells, which delays repolarization and extends the time each cell needs before it can fire again. This makes them especially useful for treating dangerous ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation. They're effective drugs, but they carry serious risks that require careful nursing assessment and patient education.

Features of Potassium Channel Blockers

These drugs prolong both the action potential duration and the effective refractory period in cardiac cells. By increasing the recovery time between beats, they prevent premature contractions (specifically early afterdepolarizations) that can trigger dangerous rhythms.

• Primarily used to treat ventricular arrhythmias, including ventricular tachycardia (VT) and ventricular fibrillation (VF)
• Also used to maintain sinus rhythm in patients with atrial fibrillation or atrial flutter
• Examples of Class III agents:
  • Amiodarone (the most widely used; also has Class I, II, and IV properties)
  • Dronedarone (Multaq)
  • Sotalol (Betapace; also has beta-blocking properties)
  • Dofetilide (Tikosyn)
  • Ibutilide (Corvert)

Mechanism of Action

Class III drugs block potassium channels, particularly the rapid component of the delayed rectifier potassium current ($I_{Kr}$). Normally, $I_{Kr}$ drives repolarization by allowing potassium to flow out of the cell. When this current is blocked, repolarization slows down, which lengthens the action potential duration and the effective refractory period.

The clinical result: cardiac cells take longer to "reset," so re-entrant circuits and ectopic foci have a harder time sustaining abnormal rhythms.

Major side effects to know:

• QT prolongation and risk of torsades de pointes (a polymorphic ventricular tachycardia that can degenerate into VF)
• Bradycardia and heart block from prolonged repolarization
• Amiodarone-specific toxicities (these are high-yield for exams):
  • Pulmonary toxicity: pneumonitis, pulmonary fibrosis
  • Thyroid dysfunction: both hypothyroidism and hyperthyroidism (amiodarone contains iodine)
  • Visual disturbances: corneal microdeposits, halos, blurred vision, photophobia
  • Hepatotoxicity
• Gastrointestinal disturbances (nausea, vomiting, diarrhea)

Cardiac Electrophysiology Review

Understanding a few key terms helps these drugs make more sense:

• Action potential: The electrical signal that triggers contraction in a cardiac cell, consisting of depolarization and repolarization phases
• Repolarization: The phase where the cell returns to its resting membrane potential, largely driven by potassium efflux
• Ion channels: Membrane proteins that control the flow of ions (sodium, potassium, calcium) and generate the action potential
• Arrhythmia: An abnormal heart rhythm caused by disruptions in the heart's electrical conduction system
• Antiarrhythmic drugs: Medications that correct arrhythmias by modifying how ion channels behave during the action potential

Nursing Considerations

1. Assess baseline and ongoing ECG, focusing on the QT interval

   • A QTc >500 ms significantly increases the risk of torsades de pointes; report this immediately

2. Monitor electrolyte levels, especially potassium and magnesium

   • Hypokalemia and hypomagnesemia worsen QT prolongation and must be corrected before and during therapy

3. Watch for signs of proarrhythmia

   • Torsades de pointes can present as palpitations, syncope, dizziness, or sudden cardiac arrest

4. Administer medications as prescribed and reinforce adherence

   • Missed doses can allow breakthrough arrhythmias

5. Screen for drug interactions that prolong the QT interval

   • Common culprits: certain antibiotics (fluoroquinolones, macrolides), antipsychotics, and antiemetics (ondansetron)

6. For patients on amiodarone, regularly assess liver, thyroid, and pulmonary function

   • Obtain baseline labs and pulmonary function tests, then repeat every 6 months
   • Annual eye exams are also recommended due to corneal deposit risk

Patient Education

• Do not stop the medication abruptly without consulting the prescriber. Sudden discontinuation can worsen arrhythmias.
• Report these symptoms promptly: palpitations, dizziness, fainting, shortness of breath, vision changes, persistent nausea or diarrhea, or unusual fatigue (which may signal thyroid dysfunction).
• Inform all healthcare providers about antiarrhythmic medication use. This is critical for avoiding dangerous drug interactions.
• Attend regular follow-up appointments, typically every 3 to 6 months, for ECG monitoring, lab work, and assessment of drug effectiveness.
• Consult the prescriber before starting any new medications, supplements, or herbal products. Many compounds affect the metabolism of antiarrhythmics or can worsen side effects (for example, St. John's wort can reduce amiodarone levels).
• Maintain heart-healthy habits: regular physical activity, a balanced diet, stress management, and smoking cessation all support the effectiveness of antiarrhythmic therapy.